Skip to main content

Home/ Dr. Goodyear/ Group items tagged lymphoma

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

https://www.iwmf.com/sites/default/files/docs/publications/serum_igm_hyperviscosity_WM_... - 1 views

www.iwmf.com/..._hyperviscosity_WM_Mar2017.pdf

Waldenstrom lymphoma Waldenstrom lymphoma cancer plasmapheresis hyperviscosity syndrome

shared by Nathan Goodyear on 31 Aug 18 - No Cached
  • Nathan Goodyear on 31 Aug 18
     
    IgM levels > 60 g/l found to predict need for plasmapheresis due to hyperviscosity syndrome.
Nathan Goodyear

Evidence-based focused review of management of hyperviscosity syndrome | Blood Journal - 0 views

www.bloodjournal.org/...2205

hyper viscosity syndrome Waldenstrom Waldenstrom lymphoma lymphoma cancer

shared by Nathan Goodyear on 31 Aug 18 - No Cached
  • Nathan Goodyear on 31 Aug 18
     
    great case study read on hyperviscosity syndrome.
Nathan Goodyear

CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burde... - 0 views

www.ncbi.nlm.nih.gov/...21526506

NK cells CD16_56 cancer lymphoma natural killer cells

shared by Nathan Goodyear on 28 Sep 18 - No Cached
  • Nathan Goodyear on 28 Sep 18
     
    Only abstract available here.  Study finds association between high tumor burden, more aggressive disease, and lower NK cell numbers.  In addition, inverse assocation with CD16/56 and LDH found.  Most likely direct tumor suppression as cause.
Nathan Goodyear

The current state and future perspectives of cannabinoids in cancer biology - 0 views

www.ncbi.nlm.nih.gov/...PMC5852356

Cancer CBD THC cannabinoids

shared by Nathan Goodyear on 19 Sep 18 - No Cached
hoangkimchi liked it
  • The activation of each of them leads to an inhibition of adenylyl cyclase via G proteins (Gi/o), which in turn activates many metabolic pathways such as mitogen‐activated protein kinase pathway (MAPK), phosphoinositide 3‐kinase pathway (PI3K), cyclooxygenase‐2 pathway (COX‐2), accumulation of ceramide, modulation of protein kinase B (Akt), and ion channels
  • phytocannabinoids, endocannabinoids, and synthetic cannabinoids
  • Action of THC in human organism relies on mimicking endogenous agonists of CB receptors—endocannabinoids
  • ...8 more annotations...
  • The upregulated expression of CB receptors and the elevated levels of endocannabinoids have been observed in a variety of cancer cells (skin, prostate, and colon cancer, hepatocellular carcinoma, endometrial sarcoma, glioblastoma multiforme, meningioma and pituitary adenoma, Hodgkin lymphoma, chemically induced hepatocarcinoma, mantel cell lymphoma)
  • concentration of endocannabinoids, expression level of their receptors, and the enzymes involved in their metabolism frequently are associated with an aggressiveness of cancer
  • CB2 receptor contributes to human epidermal growth factor receptor (HER2) pro‐oncogenic signaling and an overexpression of CB2 increases susceptibility for leukemia development after leukemia viral infection
  • endocannabinoid‐degrading enzymes are upregulated in cancer cell lines and in human tumors
  • Many cannabinoids, ranging from phytocannabinoids (THC, CBD), endocannabinoids (2‐arachidonoylglycerol, anandamide), to synthetic cannabinoids (JWH‐133, WIN‐55,212‐2), have shown ability to inhibit proliferation, metastasis, and angiogenesis in a variety of models of cancer
  • Despite some inconsistent data, the main effect of cannabinoids in a tumor is the inhibition of cancer cells’ proliferation and induction of cancer cell death by apoptosis
  • CB1 and CB2 receptor agonists stimulate apoptotic cell death in glioma cells by induction of de novo synthesis of ceramide, sphingolipid with proapoptotic activity
  • process of autophagy is upstream of apoptosis in mechanism of cell death induced by cannabinoids
Nathan Goodyear

http://www.cancernetwork.com/oncology-journal/how-we-treat-tumor-lysis-syndrome/page/0/3 - 0 views

www.cancernetwork.com/...3

"Tumor lysis syndrome" TLS cancer

shared by Nathan Goodyear on 07 Jan 19 - No Cached
  • Nathan Goodyear on 07 Jan 19
     
    Good review of diagnosis and treatment of tumor lysis syndrome. Increased risk in lymphomas and leukemia's.
Nathan Goodyear

Clinical Case Reports / Endocrine Practice - - 0 views

journals.aace.com/...EP.12.2.227

Hodgkin's lymphoma lymphoma hyercalcemia

shared by Nathan Goodyear on 17 Jan 19 - No Cached
  • Nathan Goodyear on 17 Jan 19
     
    great case study of Hypercalcemia presented with Hodgkin's. The patient was treated with IV hydration and lasix for intravascular volume depletion and kidney perfusion and to flush the calcium; prednisone and pamidronate-a bisphosphonate.
Nathan Goodyear

Non-Hodgkin's Lymphoma Reversal with Dichloroacetate - 0 views

www.hindawi.com/...414726

cancer NHL non-Hodgkin's Lymphoma Dichloroacetate DCA

shared by Nathan Goodyear on 31 May 19 - No Cached
  • Nathan Goodyear on 31 May 19
     
    Oral DCA leads to remission in NHL case study. The oral dose was 900 mg daily.
Nathan Goodyear

How We Read Oncologic FDG PET/CT | Cancer Imaging | Full Text - 0 views

cancerimagingjournal.biomedcentral.com/...s40644-016-0091-3

PET_CT PET scan CT cancer

shared by Nathan Goodyear on 20 Feb 18 - No Cached
  • In early PET literature focusing on analysis of solitary pulmonary nodules, some researchers defined malignancy based on a SUVmax threshold of greater than 2.5
  • We contend that SUV analysis has virtually no role in this setting.
  • tumours grow as spheres, whereas inflammatory processes are typically linear
  • ...35 more annotations...
  • Far more important than the SUVmax is the pattern rather than intensity of metabolic abnormality and the correlative CT findings
  • Descriptively, we define SUV < 5 as “low intensity”, 5–10 as “moderate”, 10–15 as “intense” and >15 as “very intense”
  • Evolving literature suggests that intensity of uptake is an independent prognostic factor and in some tumour subtypes superior to histopathologic characterisation.
  • aerobic glycolysis
  • Our practice of thresholding the grey and colour scale to liver as detailed above results in similar image intensity to a fixed upper SUV threshold of 8 to 10
  • The advantage of using the liver as a reference tissue is also aided by this organ having rather low variability in metabolic activity
  • When the liver is abnormal and cannot be used as a reference organ, we use the default SUV setting of an upper SUV threshold of 8
  • One of the most challenging aspects of oncologic FDG PET/CT review, however, is to recognise all the patterns of metabolic activity that are not malignant and which consequently confound interpretation
  • Many benign and inflammatory processes are also associated with high glycolytic activity
  • Future articles in the “How I Read” series will address the specific details of reading PET/CT in various cancers
  • The intensity of uptake in metastases usually parallels that in the primary site of disease
  • For example, discordant low-grade activity in an enlarged lymph node in the setting of intense uptake in the primary tumour suggests it is unlikely malignant and more likely inflammatory or reactive
  • By CT criteria the enlarged node is ‘pathologic’ but the discordantly low metabolic signature further characterises this is as non-malignant since such a node is not subject to partial volume effects and therefore the intensity of uptake should be similar to the primary site
  • The exception is when the lymph node is centrally necrotic as a small rim of viable tumour is subject to partial volume effects with expectant lower intensity of uptake; integrating the CT morphology is therefore critical to reaching an accurate interpretation
  • Small nodes that are visualised on PET are conversely much more likely to be metastatic as such nodes are subject to partial volume effects.
  • The exception to this rule is tumours with a propensity for tumour heterogeneity at different sites
  • The combination of FDG and a more specific tracer, which visualises the well-differentiated disease can be very useful to characterise this phenomenon
  • “metabolic signature”
  • For the majority of malignant processes, the intensity of metabolic abnormality correlates with degree of aggressiveness or proliferative rate.
  • a negative PET/CT study in a patient with biopsy proven malignancy would be considered false-negative
  • Warburg effect
  • There, however, are a significant minority of tumours that utilise substrates other glucose such as glutamine or fatty acids as a source of the carbon atoms required for growth and proliferation
  • This includes a subset of diffuse gastric adenocarcinomas, signet cell colonic adenocarcinomas and some sarcomas, particularly liposarcoma
  • There may be a role for other radiotracers such as fluorothymidine (FLT) or amino acid substrates in this setting.
  • Some tumours harbour mutations that result in defective aerobic mitochondrial energy metabolism, effectively simulating the Warburg effect
  • patients with hereditary paraganglioma and pheochromocytoma highlight this phenomenon
  • These have intense uptake on FDG PET/CT despite often having low proliferative rate.
  • Uterine fibroids, hepatic adenomas, fibroadenomas of the breast and desmoid tumours are benign or relatively benign lesions that can have quite high FDG-avidity.
  • Metabolic activity switches off rapidly following initiation of therapy
  • Common examples where patients have commenced active therapy but the referrer is requesting “staging” includes hormonal therapy (eg. tamoxifen) in breast cancer, oral capecitabine in colorectal cancer or high dose steroids in Hodgkin’s lymphoma
  • It is therefore critical to perform PET staging before commencement of anti-tumour therapy
  • The potential advantage of routine diagnostic CT is improved anatomic localisation and definition
  • Without intravenous contrast, additional identification of typical oncologic complications such as pulmonary embolism or venous thrombosis cannot be identified
  • If the study is performed as an “interim” restaging study after commencement of therapy but before completion, in order to reach a valid or clinically useful conclusion findings must be interpreted in the context of known changes that occur at a specific timing and type of therapy
  • The most well studied use of interim PET is in Hodgkin’s lymphoma where repeat PET after two cycles of ABVD-chemotherapy provides powerful prognostic information and may improve outcomes by enabling early change of management
  • Nathan Goodyear on 20 Feb 18
     
    good read on the PET/CT scan reading.  They mention that tumors are spheres and inflammation is linear, yet inflammation coexists with cancer; hard to simply delineate these on simple terms. I do agree aon the metabolic signature of the PET/CT scan
Nathan Goodyear

The emerging role of estrogen in B cell malignancies: Leukemia & Lymphoma: Vol 58, No 3 - 0 views

www.tandfonline.com/...10428194.2016.1213828

estrogen leukemia lymphoma ER ER beta estrogen receptor cancer

shared by Nathan Goodyear on 27 Nov 17 - No Cached
  • Nathan Goodyear on 27 Nov 17
     
    Evidence that Estrogen and ER status plays role in hematological cancer.  ER-beta agonist inhibited cell growth and induced cell death. Similar to prostate cancer.
Nathan Goodyear

Classical and Non-Classical Thyroid Hormone Intracellular Pathways Involved in T Lympho... - 0 views

www.eurekaselect.com/133018

cancer genomic signaling Lymphoma thyroid thyroid hormones non-genomic signaling

shared by Nathan Goodyear on 12 Apr 21 - No Cached
  • Nathan Goodyear on 12 Apr 21
     
    Both involved. I can only find the abstract to share here.
Nathan Goodyear

[Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-cen... - 0 views

pubmed.ncbi.nlm.nih.gov/10605421

NHL mistletoe Iscador non-Hodgkin's Lymphoma

shared by Nathan Goodyear on 15 Jan 21 - No Cached
  • Nathan Goodyear on 15 Jan 21
     
    Iscador mistletoe effective in long-term treatment and remission of NHL.
Nathan Goodyear

Case Report of a Pro-Vaccine Researcher Suggests mRNA Vaccine Might Worsen Lymphoma Cancer - 0 views

www.thegatewaypundit.com/...e-might-worsen-lymphoma-cancer

spike proteins cancer SARS-CoV-2 COVID covid19 mRNA spike protein vaccine COVID-19

shared by Nathan Goodyear on 25 Oct 22 - No Cached
  • Nathan Goodyear on 25 Oct 22
     
    Not journal article, but to be read.
‹ Previous 21 - 40 of 67 Next › Last »
Showing 20▼ items per page